Form 4: Spero Therapeutics Officer Receives Significant Equity Grants

Spero Therapeutics' multi-titled officer, Esther Rajavelu, was granted 249,000 restricted stock units and 498,000 stock options, alongside a tax-related sale of 18,442 shares.

Summary

• Esther Rajavelu, holding roles as Chief Executive Officer, Chief Financial Officer, and Chief Business Officer at Spero Therapeutics, Inc. (SPRO), reported equity transactions.
• On February 2, 2026, Rajavelu was granted 249,000 Restricted Stock Units (RSUs) under the company's 2017 Stock Incentive Plan.
• These RSUs will vest in four equal annual installments, commencing on February 2, 2027, contingent on continued service.
• Concurrently, Rajavelu acquired 498,000 stock options with an exercise price of $2.23 per share, expiring on February 2, 2036.
• The stock options will vest 25% on February 2, 2027, with the remaining portion vesting in 36 equal monthly installments thereafter, also subject to continued service.
• A disposition of 18,442 shares of common stock occurred on February 2, 2026, at a price of $2.2 per share.
• This sale was a non-discretionary "sell to cover" transaction, executed automatically to satisfy tax withholding obligations related to the vesting of RSUs.
• Following these transactions, Rajavelu beneficially owns 1,100,008 shares of common stock and 498,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive signal, as it reflects continued executive commitment through significant equity grants, although the tax-related sale slightly tempers the overall sentiment.

Positives

• Significant equity grants (249,000 RSUs and 498,000 stock options) to a key officer, aligning management's interests with shareholder value.
• The grants are tied to continued service, incentivizing long-term commitment from a multi-titled executive.

Negatives

• A sale of 18,442 shares occurred, although it was a non-discretionary "sell to cover" for tax obligations, it still represents a reduction in direct share ownership.

Future Outlook

The vesting schedules for the RSUs and stock options extend through February 2, 2027, and beyond, with the options expiring in 2036, indicating a long-term incentive structure for the executive.

Management Comments

• Esther Rajavelu holds the titles of Chief Executive Officer, Chief Financial Officer, and Chief Business Officer.
• The sale of 18,442 shares was required to cover tax withholding obligations and does not represent a discretionary trade.

Industry Context

StockSavvy.ai notes that equity compensation, particularly through RSUs and stock options with multi-year vesting schedules, is a standard practice in the biotechnology and pharmaceutical industries. This approach is designed to attract and retain top executive talent and align their long-term interests with the company's performance and shareholder value creation.

Comparison to Industry Standards

• Equity grants of this magnitude to a C-suite executive are common in the biotech sector, especially for companies like Spero Therapeutics, which are often in development stages and rely on long-term incentives.
• For example, similar grants are seen at comparable small-to-mid cap biotechs such as Atea Pharmaceuticals or Finch Therapeutics, where executive compensation packages frequently include substantial equity components to incentivize drug development milestones and market success.
• The "sell to cover" mechanism for tax obligations is also a standard industry practice for equity vesting.

Stakeholder Impact

• Shareholders: The equity grants align the executive's long-term interests with shareholder value, potentially fostering greater commitment to company performance.
• Employees: May signal stability in leadership and a commitment to executive retention.

Next Steps

• The RSUs will begin vesting in four equal annual installments starting February 2, 2027.
• The stock options will begin vesting 25% on February 2, 2027, with the remainder vesting in 36 equal monthly installments thereafter.

Key Dates

Recommendation

This Form 4 filing primarily details routine executive compensation in the form of equity grants and a non-discretionary tax-related stock sale. While the grants align executive incentives with long-term company performance, the filing itself does not provide new fundamental information about the company's operational or financial health that would warrant a change in investment recommendation. It's a standard disclosure of insider activity.

Keywords

Spero Therapeutics, SPRO, Form 4, insider trading, equity grant, restricted stock units, RSUs, stock options, executive compensation, beneficial ownership, sell to cover, officer transactions